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Abstract 
microRNA-122 (miR-122) is increasingly being measured in pre-clinical and clinical 
settings due to greater sensitivity and hepatic specificity compared to the gold standard 
liver injury biomarker alanine aminotransferase (ALT). In pre-clinical studies, various 
culling methods can be employed prior to collection of blood samples, including lethal 
injection with pentobarbital sodium (Pentoject). However, little is known about whether 
such an approach could alter the circulating levels of miR-122 and compromise the 
interpretation of data.  We therefore exposed C57BL/6J mice to saline or the model 
hepatotoxin acetaminophen and collected blood samples pre-cull (via tail bleed) and post-
cull (via cardiac puncture following exposure to a rising concentration of CO2 or 
intraperitoneal injection of Pentoject).  Compared to pre-cull levels there was a significant 
increase in serum miR-122 level in mice culled with CO2 and, to a much greater extent, 
in mice culled with Pentoject. As a result, whilst the serum level of miR-122 increased in 
Pentoject-culled animals exposed to acetaminophen, the higher level in saline-treated 
mice rendered this difference statistically non-significant, in contrast to findings in 
animals culled with CO2.  ALT levels were unaffected by sacrifice method.  Consistent 
with the in vivo findings, exposure of primary mouse hepatocytes to Pentoject provoked 
a rapid and concentration-dependent release of miR-122 into the culture media.  Thus, for 
optimal design and interpretation of data from pre-clinical liver injury studies in which 
miR-122 is to be used as a biomarker, we recommend that blood samples are collected 
pre-cull whenever possible, and that lethal injection with Pentoject is avoided. 
 
  
Introduction 
Drug-induced liver injury (DILI) is an important human health concern 1. Indeed, 
paracetamol (acetaminophen; APAP) overdose is the most frequent cause of DILI in the 
Western world, resulting in approximately 38,000 emergency hospital admissions per 
annum in England alone 2. Moreover, DILI continues to impede the development of novel 
medications by the pharmaceutical industry. As a result, there is an increasing need for 
new, sensitive and organ-specific biomarkers to assess the safety of new and/or existing 
drugs 3. One such biomarker, microRNA-122, represents 75 % of the total hepatic miRNA 
content and exhibits exclusive hepatic expression 4.  In pre-clinical and clinical settings, 
we and others have shown that miR-122 has higher sensitivity, with respect to dose and 
time, than alanine aminotransferase (ALT) and other clinical chemistry parameters as a 
biomarker of APAP-induced liver injury 4-6.  Due to its high clinical incidence, APAP-
induced liver injury has been extensively studied in pre-clinical contexts 7. Indeed, liver 
injury can be induced in rodents with a single dose of APAP, and several clinical 
phenotypes are well preserved in this animal model 7, 8. miR-122 is now commonly 
measured in these instances, alongside ALT, to detect liver injury at the earliest time point 
3, 9. In such studies, at the appropriate time point, blood samples are commonly taken via 
tail bleed (pre-cull) or cardiac puncture (post-cull). In the latter case, one popular method 
of culling is via lethal injection with the anaesthetic pentobarbital sodium (Pentoject). In 
the field of veterinary anaesthesia it is known that extravascular administration of 
pentobarbital sodium can cause substantial tissue irritation 10.  However, little research 
has been carried out to investigate if there is an effect of this or other commonly-used 
culling methods on circulating levels of sensitive liver injury markers such as miR-122. 
Notably, Yu et al. and Cao et al. provided evidence for hepatotoxicity in rats following 
repeated high doses of Pentoject 11, 12, but there has yet to be any research into whether 
or not an acute effect could occur after a single lethal dose. Therefore, the aim of this 
investigation was to determine if lethal injection with Pentoject could affect serum miR-
122 levels. Such knowledge is vital for the correct interpretation of existing biomarker 
data, and for the optimal design of future pre-clinical studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & methods 
Animal studies 
All animal experiments were conducted according to the Animals (Scientific Procedures) 
Act 1986 guidelines.  Male C57BL/6J mice (Charles River, UK), aged 7 – 9 weeks, were 
divided into three groups according to the treatment they received: saline (vehicle 
control), 35 mg/kg APAP (sub-toxic dose) or 300 mg/kg APAP (toxic dose). The choice 
of sub-toxic and toxic doses was based on historical ALT data. For all experiments, food 
was withdrawn 16 h prior to APAP administration, which was via intraperitoneal (IP) 
injection. After 24 h, tail bleeds were performed on all animals, and then half of the mice 
from each group were culled via exposure to a rising concentration of CO2, with the other 
half culled via IP injection of 1000 mg/kg Pentoject. In both cases, blood was then 
immediately removed by cardiac puncture. Blood samples were left to clot at room 
temperature before separating the serum via centrifugation. Serum was stored at -80 oC 
until analysis, which excluded any haemolysed samples.  Liver tissue samples were fixed 
in 4 % paraformaldehyde before transferring to 70 % ethanol for storage.  
Murine primary hepatocyte experiments 
Murine primary hepatocytes were isolated from C57BL/6J mice using a method 
previously described by Li et al. 2010, with some minor modifications 13.  In brief, 
livers were perfused with wash buffer containing ethylene diamine tetraacetic acid 
followed by a digestion buffer containing CaCl2 and type IV collagenase (Sigma-
Aldrich, Missouri, USA). Hepatocytes were suspended William’s E medium 
supplemented with 10 % fetal bovine serum (FBS), 2 mM L-glutamine, 100 nM 
dexamethasone, 10 μg/mL insulin, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite, 
100 U/mL penicillin and 01. mg/mL streptomycin. The cells were seeded at 1 x 105 
cells/cm2 and incubated at 37 °C in a 5 % CO2 atmosphere. After 3 h the media and 
non-attached cells were removed and replaced with media lacking FBS. After a 
further 16 h the cells were exposed to the indicated concentrations of Pentoject for 5 
min. Cellular ATP levels were determined using the CellTiter-Glo luminescent assay 
(Promega, Wisconsin, USA) according to the manufacturer’s instructions. Cellular 
lactate dehydrogenase (LDH) levels were determined using the Cytotoxicity 
Detection Kit (Sigma-Aldrich) according to the manufacturer’s instructions. The 
LDH content of the culture media could not be determined due to reaction of the 
assay reagent with high concentrations of Pentoject. 
 
Quantification of miR-122 levels  
miRNA was extracted and purified from 20 µL serum or 100 µL cell media using a 
commercially available miRNeasy kit followed by an RNeasy MinElute Cleanup Kit 
(Qiagen, Venlo, Netherlands), in accordance with the manufacturer’s instructions.  miR-
122 level was measured using Taqman-based quantitative polymerase chain reaction 
(qPCR) as previously described3. Each miR-122 measurement involved duplicate qPCR 
repeats of the reverse transcription cDNA product as described by Sharkey et al. 14. For 
serum analysis, miR-122 Ct values were normalised to the level of endogenous let-7d. 
For culture media analysis, miR-122 copy numbers were calculated through the use of a 
standard curve generated with a synthetic miR-122 oligonucleotide.  For the spiking 
experiment, a pool of control serum samples was directly supplemented with 25 mg/mL 
(estimated maximum blood concentration in vivo) or a 10-fold lower concentration of 
Pentoject prior to miRNA extraction, purification and quantification. These samples were 
tested in triplicate and an overall average recorded.  
Quantification of ALT levels  
Serum ALT levels were determined using a Thermo Infinity ALT Liquid Stable Reagent-
based kinetic assay (Thermo Scientific, Waltham, MA) according to the manufacturer's 
instructions and as previously described 3. 
 
Hepatic histological assessment  
To enable histopathological assessment, fixed liver tissues were paraffin-embedded and 
4 µm sections were stained with haematoxylin and eosin (H&E).   
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San 
Diego, CA).  A Shapiro Wilk test was used to assess normality of the data, followed by 
Mann-Whitney U tests or Unpaired t tests, as appropriate, to assess statistical 
significance, defined as P < 0.05.   
 
 
 
 
 
Results 
Lethal injection with Pentoject raises basal serum miR-122, but not ALT, levels 
As expected, serum ALT levels were significantly increased in response to the toxic, but 
not sub-toxic, dose of APAP in animals culled by either rising CO2 or Pentoject, when 
blood was sampled via cardiac puncture (Fig. 1A). There was no significant difference 
between the serum ALT levels in vehicle-treated mice culled by the two methods (Fig. 
1A). There was a significant increase in serum miR-122 levels in response to the toxic 
dose of APAP in animals culled by rising CO2 (Fig. 1B). However, there was also a 
significant increase in the level of serum miR-122 in vehicle-treated animals culled by 
Pentoject, compared with those culled by rising CO2 (Fig. 1B). As a result, whilst the 
serum level of miR-122 increased in Pentoject-culled animals exposed to the toxic dose 
of APAP, the higher level in vehicle-treated mice rendered this difference statistically 
non-significant (Fig. 1B). Therefore, Pentoject raises basal serum miR-122 level and 
impacts on the statistical interpretation of responses to APAP.  Regardless of culling 
method, we observed multifocal to coalescing coagulative centrilobular necrosis in the 
livers of mice exposed to the toxic dose of APAP (Fig. 1C).  
 
Serum miR-122 levels increase post-mortem, particularly following lethal dosing with 
Pentoject 
 
To ensure that the higher basal serum level of miR-122 in animals culled with Pentoject 
was not an experimental artefact, we quantified the biomarker in the serum of the same 
animals sampled via tail bleed (i.e. pre-cull). Regardless of the culling method, serum 
miR-122 was significantly higher in samples obtained via cardiac puncture (i.e. post-cull) 
compared with those obtained via tail bleed (Fig. 2). Moreover, there was no difference 
in the levels of miR-122 in tail bleed samples of vehicle-treated mice that went on to be 
culled via rising CO2 or Pentoject (Fig. 2), indicating that serum miR-122 levels rise post-
mortem. However, the rise in serum miR-122 in animals culled with Pentoject was greater 
than that observed in animals culled with rising CO2 (Fig. 2B), accounting for the 
statistical discrepancy in the miR-122 response to the toxic dose of APAP in blood 
samples obtained via cardiac puncture (Fig. 1B). Indeed, our analysis of tail bleed samples 
revealed a significant increase in serum miR-122 levels in response to the toxic dose of 
APAP in the animals that went on to be culled with Pentoject (Fig. 2B), indicating that 
the loss of statistical significance in samples collected post-cull was directly related to 
Pentoject.   
 
Pentoject provokes the release of miR-122 from primary hepatocytes  
 
We next isolated primary hepatocytes from mice and exposed them to Pentoject to further 
assess its ability to provoke the release of miR-122 from liver cells. Despite an extensive 
literature review, we were unable to find a maximum blood concentration of sodium 
pentobarbital following bolus IP injection of Pentoject. Therefore, we assumed that the 
30 mg dose of Pentoject would be distributed within a total blood volume of 1.2 mL, 
giving a concentration of 25 mg/mL. As the local concentration was likely to be higher 
following IP injection, we exposed the hepatocytes to up to 100 mg/mL Pentoject for 5 
min. At and above 10 mg/mL Pentoject provoked a significant and concentration-
dependent increase in the number of miR-122 molecules in the culture media, 
concomitant with decreases in cellular ATP and LDH content, indicative of the loss of 
hepatocyte integrity (Fig. 3A). These data further confirm that Pentoject can provoke a 
rapid release of miR-122 from mouse liver cells.   
 
Pentoject does not cause assay-related perturbations  
 
Finally, to confirm that the higher levels of miR-122 in samples obtained from Pentoject-
culled mice were not assay-related, we performed extraction, purification, reverse 
transcription and qPCR analysis using a pool of control serum samples that was directly 
supplemented with saline or Pentoject. There was no change in the level of miR-122 in 
samples spiked with Pentoject (Fig. 3B), further indicating that Pentoject directly affects 
liver cells and causes an increase in circulating levels of miR-122.  
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Given that DILI continues to be a clinical burden and barrier to the development of novel 
drugs, there is a clear need to qualify new biomarkers that can better predict human health 
hazard on the basis of pre-clinical studies and early phase clinical trials. Previously, we 
and others have shown that miR-122 is a more sensitive marker of DILI than ALT and 
other clinical chemistry parameters 4-6. Moreover, recently, a panel of novel DILI 
biomarkers, including miR-122, received regulatory letter of support status from the FDA 
(July 2016) and the EMA (September 2016) for their further qualification as DILI 
biomarkers within a defined context of use. However, much remains to be learnt about 
miR-122 as a liver injury biomarker in different pre-clinical and clinical settings and as 
such, regulatory feedback has provided clear support for the incorporation of biomarkers 
such as miR-122 into exploratory DILI studies to further define whether such markers are 
fit-for-purpose.   
Our current findings add significantly to the understanding of the utility of miR-122 as a 
putative DILI biomarker in vivo. We have demonstrated that, compared to pre-cull levels, 
there is a significant increase in serum miR-122 level in mice culled with CO2 and, to a 
much greater extent, in mice culled with Pentoject. In the latter case, the increase in 
circulating miR-122 in control mice influences the statistical differentiation of the degree 
of liver injury following exposure to the model hepatotoxin APAP. The rise in circulating 
miR-122 after culling with CO2 likely reflects early perturbations of the liver post-mortem 
whilst the rapid and direct effect of Pentoject provokes additional increases in the level 
of miR-122 in post-cull serum samples. Indeed, although our histopathological analysis 
did not reveal any overt perturbations that distinguished the livers of Pentoject and CO2 
culled animals, the in vitro experiments demonstrated that Pentoject can cause a rapid 
release of miR-122 from hepatocytes at concentrations that are relevant to those likely 
attained in vivo. Holman et al. recently provided evidence for the release of miR-122 
within extracellular vesicles (such as exosomes) prior to overt cell death 15. In contrast, 
ALT is known to be passively released into the serum following liver cell necrosis 16. 
These observations may account for the apparent difference in sensitivity of the two 
markers to Pentoject-induced hepatic perturbation.Further work will be needed to clarify 
the precise mechanism underlying our observations. In addition, it will be important to 
determine whether miR-122 levels change in response to lethal doses of other anaesthetics 
that are used in pre-clinical studies, and whether the observed effect is conserved in other 
mouse strains and species. Finally, it will be valuable to investigate whether the response 
of miR-122 is mirrored by that of other liver-related microRNAs, such as miR-192, as 
well as those associated with discrete organs such as the kidney.   
Conclusion 
The findings of this study highlight the need to carefully consider the method of culling 
used in pre-clinical studies that are designed to measure liver injury via the quantification 
of serum miR-122 levels. At least until further work has clarified the underlying 
pathological mechanism, we recommend that when miR-122 is to be used as a biomarker 
blood samples should ideally be collected pre-cull (e.g. by tail bleed). When this is not 
feasible, IP injection of Pentoject should be avoided as a culling method.  
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Figures  
 
 
Figure 1 – Lethal injection with Pentoject raises basal serum miR-122, but not ALT, 
levels. Mice were exposed to vehicle control (saline), a sub-toxic dose (35 mg/kg) of 
APAP or a toxic dose (300 mg/kg) of APAP for 24 h. Blood samples were removed, via 
cardiac puncture, from mice following exposure to rising CO2 or IP injection with a lethal 
dose of Pentoject. Serum levels of (A) ALT and (B) miR-122 were quantified, with the 
latter normalised to endogenous reference let-7d. Data is presented as mean -/+ SEM, 
with 9-12 animals per group. Statistical significance was determined by Mann-Whitney 
U test (* P < 0.05, ** P < 0.01, *** P < 0.001).  (C) H&E staining of representative livers 
from each group, showing marked centrilobular necrosis with the toxic dose of APAP.  
Scale bars indicate 500 µm. 
 
  
Figure 2 – Serum miR-122 levels increase post-mortem, particularly following lethal 
dosing with Pentoject. Mice were exposed to vehicle control (saline), a sub-toxic dose 
(35 mg/kg) of APAP or a toxic dose (300 mg/kg) of APAP for 24 h. Tail bleeds were 
performed prior to culling by (A) exposure to rising CO2 or (B) injection with Pentoject. 
Serum levels of miR-122 were quantified and normalised to endogenous reference let-7d. 
Data is presented as mean -/+ SEM, with 9-12 animals per group. Statistical significance 
was determined by Mann-Whitney U test (* P < 0.05, ** P < 0.01, *** P < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3 – Pentoject provokes the release of miR-122 from primary hepatocytes. (A) 
Levels of miR-122 in the media and cellular contents of ATP and LDH in primary mouse 
hepatocytes exposed to the indicated concentrations of Pentoject for 5 min. Data is 
presented as mean -/+ SEM of triplicate wells for a representative experiment. Statistical 
significance notifies differences between vehicle control (0 mg/mL) and other conditions, 
according to unpaired t tests (* P < 0.05, ** P < 0.01, *** P < 0.001). (B) miR-122 levels 
in serum spiked with Pentoject. miR-122 levels were quantified in pooled control serum 
directly supplemented with saline or the indicated concentrations of Pentoject. Data is 
presented as mean -/+ SEM of triplicate measurements. None of the groups were 
significantly different, according to Mann-Whitney U tests. 
 
